Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts
Exelixis, Inc. (NASDAQ: EXEL) Delayed: 51.56 +0.21 (0.41%)
Previous Close $51.35    52 Week High $17.00 
Open $51.39    52 Week Low $3.55 
Day High $52.07    P/E N/A 
Day Low $50.88    EPS $-1.33 
Volume 1,716,006